Alzheimers disease
Conditions
Interventions
experimental group:Patients with moderate to severe AD in the Third Affiliated Hospital of Nanjing Medical University were included in the study, and oral drugs combined with LVA surgery were performe
Control group:Patients with moderate to severe AD in the Third Affiliated Hospital of Nanjing Medical University were included, and oral medication was simply administered, and the demographic data, m
Sponsors
Changzhou No.2 People’s Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (All 4 items must be met) 1. Meet the diagnostic criteria for AD in NIA-AA; 2. Biological characteristics consistent with AD (A: decreased CSF Aß42 or Aß42/Aß40 ratio or increased Aß-PET uptake; T: elevated cerebrospinal fluid p-tau181 or cerebrospinal fluid p-tau217 or plasma p-tau217 or increased tau-PET uptake); 3.AD the symptom stage was in the intermediate (CDR score 2.0) and late stage (CDR score 3.0). 4. Patients and their families agree to participate in clinical studies.
Exclusion criteria
Exclusion criteria: (Any 1 item matches) 1. Dementia of non-AD origin; 2. Serious cardiovascular system diseases, respiratory diseases, liver diseases, kidney diseases, hematologic diseases or malignant tumors, etc.; 3. Previous history of bilateral neck surgery; 4. Presence of other contraindications to surgery; 5. Severe visual and hearing impairment, paralysis of limbs and inability to walk independently; 6. Patients and their families do not agree to participate in the clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 90 days postoperative plasma AD biomarkers; | — |
Secondary
| Measure | Time frame |
|---|---|
| Head MRI examination;Rating of AD related scales; | — |
Countries
China
Contacts
Public ContactFang Liu
Changzhou No.2 People’s Hospital
Outcome results
None listed